Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
megakaryocyte-derived extracellular vesicles
- Development stage
- Preclinical
- Lead developer
- University of Delaware
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Megakaryocyte-derived extracellular vesicles (MkEVs) are a specialized class of biologic therapeutic agents and cell-derived nanoparticles. These vesicles are typically derived from megakaryocytes, which can be generated through the differentiation of human pluripotent stem cells (hPSCs). MkEVs possess a natural tropism for hematopoietic stem and progenitor cells (HSPCs) within the bone marrow, a property that enables them to serve as highly efficient delivery vehicles for therapeutic cargoes, including gene editing tools, mRNA, and small molecules. Beyond their utility in drug delivery, MkEVs have been shown to directly stimulate thrombopoiesis, leading to increased platelet counts. They are currently being investigated for the treatment of a wide range of conditions, including genetic disorders, infectious diseases, and hematopoietic disorders such as thrombocytopenia, anemia, and hemoglobinopathies.
- Other names
- megakaryocyte-derived extracellular vesiclesMkEVsmegakaryocyte-derived EVsMk-derived EVs
Beyond the preview
Go deeper on megakaryocyte-derived extracellular vesicles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on megakaryocyte-derived extracellular vesicles.